Search Results
Mar 03, 2026, 07:00 ET CalciMedica Reports 2025 Financial Results and Provides Clinical Updates
an animal model of PAH, CM5480 restored or improved multiple disease-affected pathways and functions—including heart contraction and cardiac output, gene expression profiles, DNA repair, and metabolism. Treatment with CM5480 also significantly reduced right ventricular dysfunction (RVD) both as a monotherapy
More news about: CalciMedica, Inc.
Mar 03, 2026, 02:51 ET Senhwa Biosciences Signs Major Strategic MOU with Y Combinator-Backed AI Biotech Company CellType to Accelerate the Evolution of CX-4945 into Version 2.0 and Reshape the Global Immunotherapy Landscape
biologist Dr. David van Dijk. The company is backed by Y Combinator (Winter 2026). Its proprietary AI platform applies large language models to single-cell gene expression—the first of its kind—enabling sophisticated decoding of complex tumor microenvironment (TME) signaling.Through the original research
More news about: Senhwa Biosciences, Inc.
Mar 02, 2026, 17:58 ET REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses
REGENXBIO, Inc. (NASDAQ: RGNX) securities between February 9, 2022 and January 27, 2026. REGENXBIO is a clinical-stage biotechnology company providing gene therapies that deliver functional genes to cells with genetic defects in the United States.
More news about: Robbins LLP
Mar 02, 2026, 11:45 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline
COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene therapy being developed to slow the progression of HD. During the Class Period, uniQure
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 02, 2026, 11:30 ET GLP-1 drugs associated with reduced need for emergency care for migraine
with people starting topiramate, those starting GLP-1 drugs were 48% less likely to start valproate, 42% less likely to start calcitonin gene-related peptide (CGRP) monoclonal antibodies, 35% less likely to start tricyclic antidepressants, and 23% less likely to start the class of drugs called
More news about: American Academy of Neurology
Mar 02, 2026, 11:03 ET February's Top 10 Celebrity Real Estate News: Billy Joel, Marilyn Monroe & Hulk Hogan
of a wealthy English family, including a formal dining room, a sitting room, a library, and lovely gardens.Gene Simmons Lowers Mansion PriceKiss band leader Gene Simmons buys and sells homes almost as often as he bites his tongue, often reshuffling his portfolio between California,
More news about: Top Ten Real Estate Deals
Mar 02, 2026, 08:30 ET Xtalks Announces its Life Science Webinar Calendar for March 2026
www.xtalks.com to see our upcoming webinars:CELL AND GENE THERAPYMar 12 - How to Build a Measurable Evidence Engine for Cell, Gene and RNA TherapiesCLINICAL TRIALSMar 4 - Accelerate Your Study: Harnessing AI and Automation
More news about: Xtalks
Mar 02, 2026, 08:30 ET Spinogenix Announces FRAXA Research Foundation Support for PIs Leading Phase 2b Trial of Investigational Therapy SPG601 for People with Fragile X Syndrome (FXS)
SyndromeFragile X Syndrome (FXS) is the leading inherited form of intellectual disability and a known cause of autism that results from the silencing of the Fmr1 gene. FXS is an orphan disease affecting approximately 1 in 4-5000 men and 1 in 6-8000 women globally. In addition to intellectual disability, FXS patients
More news about: Spinogenix
Mar 02, 2026, 08:22 ET Pioneering Investigator Dr. Dimitra Skondra Appointed Vice Chair of Research for Ophthalmology
noninvasive biomarkers for detecting early signs of neurological and cardiovascular disease. She will bring multiple clinical trials to NYU Langone, including gene therapy trials for AMD and novel systemic treatments, positioning the institution at the forefront of retinal disease innovation and precision medicine.Clinical
More news about: NYU Grossman School of Medicine and NYU Langone Health
Mar 02, 2026, 08:00 ET Efor strengthens its North American presence with the acquisition of DynamixE
(North Carolina, Massachusetts, California, Texas, New Jersey, and Pennsylvania), the company focuses exclusively on the U.S. biologics, cell and gene therapy biomanufacturing sites for pharmaceutical and biotechnology organizationsThe alliance builds on an already active partnership between
More news about: Efor
Mar 02, 2026, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field of AAV gene therapy. REGENXBIO is advancing a late-stage pipeline of one-time treatments for rare and retinal diseases,
More news about: REGENXBIO Inc.
Mar 02, 2026, 06:00 ET Argo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer
nearly 20 years of Wall Street sell-side experience and is widely recognized for her in-depth research on novel therapies, with a focus on RNA therapies, gene and cell therapies, and emerging modalities in rare diseases and oncology.
More news about: Argo Biopharmaceutical Co., Ltd
Feb 28, 2026, 09:00 ET Well-grounded Confidence! How China's domestic growth drivers propel a strong start to its 15th Five-Year Plan
industrial and commercial sectors. China's NEV production and sales have ranked first globally for 11 consecutive years; cutting-edge technologies like gene editing and cell therapy have provided new solutions for treating complex diseases. The new system for mobilizing resources nationwide has helped break
More news about: China.org.cn
Feb 27, 2026, 09:20 ET RGNX SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026
2026, REGENXBIO issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Faruqi & Faruqi, LLP
Feb 27, 2026, 09:19 ET Atrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic Cardiomyopathies
LinkedIn.About PRKAG2 SyndromePRKAG2 syndrome is a rare, autosomal dominant, early-onset cardiomyopathy caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMPK. Mutations enhance AMPK activity leading to abnormal glycogen accumulation in heart muscle cells
More news about: Atrium Therapeutics
Feb 26, 2026, 22:06 ET RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit
defendants provided investors with material information concerning REGENXBIO's plan to develop and commercialize its product candidate RGX-111, a one-time gene therapy for the treatment of severe Mucopolysaccharidosis Type I, also known as Hurler syndrome. Defendants' statements included, among other things,
More news about: THE ROSEN LAW FIRM, P. A.
Feb 26, 2026, 16:09 ET Head and Neck Cancer Therapeutics Market to Reach USD 2.6 Billion by 2032, Driven by Immunotherapy and Precision Oncology - Credence Research Inc.
traction due to their ability to boost anti-tumor immune responses and extend survival in certain settings.For instance, GeoVax's Phase 2 trial of gene therapy Gedeptin combined with pembrolizumab (Keytruda) in recurrent head and neck cancer aims for pathologic complete responses in 36 patients, reflecting
More news about: Credence Research Inc.
Feb 26, 2026, 16:03 ET BioLife Solutions Reports Fourth Quarter and Full Year 2025 Financial Results from Continuing Operations
Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, today announced financial results for the fourth quarter and full year 2025, and introduced 2026 financial guidance.
More news about: BioLife Solutions, Inc.
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX
2026, Regenxbio issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular
More news about: Pomerantz LLP
Feb 26, 2026, 15:17 ET INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in uniQure N.V. of Class Action Lawsuit and Upcoming Deadlines - QURE
from the U.S. Food and Drug Administration (FDA) during a recent pre-Biologics License Application (BLA) meeting regarding AMT-130, an investigational gene therapy for Huntington's disease (HD)." The press release stated that, "based on the discussions at the meeting, uniQure believes that the FDA currently
More news about: Pomerantz LLP
Feb 26, 2026, 11:49 ET Cost of a Basic American Life Continued to Rise in 2024, Outpacing Wages and Headline Inflation, According to Ludwig Institute Report
@LISEP_org.About Gene LudwigIn addition to his role as LISEP chair, Gene Ludwig is a managing partner of Canapi LLC, a financial technology venture fund. He is the founder and CEO of Ludwig
More news about: Ludwig Institute for Shared Economic Prosperity
Feb 26, 2026, 11:30 ET Children's Hospital of Philadelphia and Penn Medicine Launch First CRISPR-Based Platform to Pinpoint Drivers of Acute Myeloid Leukemia in Patient Cells
vectors and delivery methods to introduce CRISPR components directly into primary leukemia cells, achieving high gene-editing efficiency. Using this platform, the team screened hundreds of gene edits simultaneously to find edits that reduced or increased cell growth, indicating genes that affect cancer
More news about: Children's Hospital of Philadelphia
Feb 26, 2026, 11:00 ET uniQure N.V. Stock Alert: QURE Stockholders Who Lost Money in the Company Should Contact Robbins LLP for Information on How to Recover Their Losses
acquired uniQure N.V. (NASDAQ: QURE) ordinary shares between September 24, 2025 and October 31, 2025. uniQure is a biotechnology company developing gene therapies for rare diseases.
More news about: Robbins LLP
Feb 26, 2026, 10:00 ET GEMMABio Announces First Patient Dosed in CHARISMA Trial of GB221, Investigational Next‑Generation Gene Therapy for Spinal Muscular Atrophy Type 1 (SMA1)
GB221 is an investigational, next‑generation gene therapy for SMA1 developed to express SMN1 in motor neurons. The absence of functional SMN1 protein in motor neurons is the underlying cause of SMA. GB221 is a one-time gene therapy that consists of an adeno‑associated virus (AAV)
More news about: GEMMA Biotherapeutics
Feb 26, 2026, 08:00 ET Orsini Now Distributing Gene Therapies LYFGENIA™, ZYNTEGLO™, SKYSONA™
one-time ex-vivo LVV gene addition therapy approved for eligible patients with transfusion-dependent beta-thalassemia who require regular red blood cell (RBC) transfusions, in which functional copies of a modified form of the beta-globin gene (βA-T87Q-globin gene) is added into a patient's
More news about: Orsini